Generic DNA and protein

Generic DNA and protein refers to the broad classes of biological macromolecules that serve as the primary targets for the majority of pharmacological agents. DNA (Deoxyribonucleic acid) is the fundamental repository of genetic information; drugs targeting DNA, such as alkylating agents (e.g., cisplatin) and intercalators (e.g., doxorubicin), are primarily used in oncology to inhibit replication and induce apoptosis in malignant cells (StatPearls, 2023). Proteins, including enzymes, receptors, ion channels, and transporters, represent the most diverse and common class of drug targets, facilitating nearly all cellular processes from signal transduction to metabolism (Nature Reviews Drug Discovery, 2018). Because this term encompasses the entirety of the genome and proteome, it does not describe a specific, actionable therapeutic target but rather a high-level categorization of molecular entities. Therapeutic interventions targeting these molecules range from non-specific chemical modifications to highly selective interactions designed to modulate specific biological pathways (NIH, 2024). The interaction between drugs and these macromolecules is the basis of molecular pharmacology and drug design, though safety concerns often arise from the lack of specificity when targeting these ubiquitous structures.

Other names

Generic DNA and proteinsDNA and proteinsBiological macromoleculesNucleic acids and polypeptides

Drugs targeting DNA typically function by forming covalent adducts (alkylation), inserting between base pairs (intercalation), or inducing strand breaks to prevent replication and transcription. Drugs targeting proteins generally act as inhibitors, activators, or modulators by binding to active, allosteric, or orthosteric sites to alter biological function.